Analysis of Clinical Parameters, Drug Consumption and Use of Health Resources in a Southern European Population with Diabetes That Did Not Contract COVID-19: A Longitudinal Big Data StudyObservational Study Published on 2022-06-022022-10-05 Journal: International Journal of Environmental Research an [Category] 임상, [키워드] affected age Care change chronic disease clinical clinically collected Consumption COVID-19 COVID-19 infection diabetes Diabetic diagnosed drug General population Health health resources individual lifestyle lockdown longitudinal means measure pandemic Patient patients pharmacological Population resource resulting service Southern European Spain Spread student t -test variable virus was used [DOI] 10.3390/ijerph19116835 PMC 바로가기 [Article Type] Observational Study
Molnupiravir combined with different repurposed drugs further inhibits SARS-CoV-2 infection in human nasal epithelium in vitro다양한 용도 변경 약물과 결합된 몰누피라비르는 시험관 내 인간 비강 상피에서 SARS-CoV-2 감염을 추가로 억제합니다Article Published on 2022-06-012022-09-11 Journal: Biomedicine & pharmacotherapy = Biomédecine & phar [Category] COVID19(2023년), SARS, 변종, 신약개발, 치료제, [키워드] accelerated acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Air-liquid interface antiviral activity Antiviral treatment antiviral treatments antivirals caused cellular Clinical efficacy clinical testing clinically Combination combinations complex Compound Concentration coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 drug drug combination drug combinations Drug repurposing effective effective antiviral treatment effort Emergency use evaluated highlighting identify Immunity in vitro in vitro model inhibit inhibiting molnupiravir nasal epithelium Potential treatment Repurposed drug SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 replication selected severe acute respiratory syndrome Coronavirus short duration tested the vaccine These data Treatment Vaccine variant worldwide pandemic [DOI] 10.1016/j.biopha.2022.113058 PMC 바로가기 [Article Type] Article
Clinical characterization of COVID-19 breakthrough infections, PhilippinesCOVID-19 돌발 감염의 임상 특성, 필리핀Article Published on 2022-06-012022-09-11 Journal: Journal of Clinical Virology [Category] COVID19(2023년), SARS, 치료기술, [키워드] administration Alpha Asymptomatic Beta booster dose Breakthrough infection breakthrough infections characterized clinical clinically CoronaVac COVID-19 Ct values Delta VOC Evidence HCW HCWs healthcare worker Healthcare workers Inactivated vaccine majority male PCR Philippines risk SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 infections SARS-CoV-2 transmission sequenced severe cases significantly lower symptomatic viral loads VOCs [DOI] 10.1016/j.jcv.2022.105157 PMC 바로가기 [Article Type] Article
Immunogenicity of the mRNA-1273 COVID-19 vaccine in adult patients with inborn errors of immunity선천성 면역이상이 있는 성인 환자에서 mRNA-1273 코로나19 백신의 면역원성Controlled Clinical Trial Published on 2022-06-012022-09-12 Journal: The Journal of Allergy and Clinical Immunology [Category] COVID19(2023년), MERS, SARS, 변종, 임상, 진단, 치료기술, [키워드] acute respiratory syndrome All participant antibodies antibody Antibody Response Antibody titer baseline binding Cellular immune response CID clinically cohorts comparable Complication complications Control coronavirus correlated COVID-19 COVID-19 vaccination COVID-19 vaccine CVID deficiencies deficiency dose first vaccination healthy controls humoral immune response Immunity immunodeficiency immunogenic immunogenicity immunosuppressive drug Inborn error inborn errors of immunity increased risk Level Mild mRNA-1273 mRNA-1273 COVID-19 vaccine multicenter Neutralizing antibodies Patient patient group patients patients with CVID phagocyte Primary immunodeficiency disorders SARS-CoV-2 second vaccination seroconversion rate T-cell T-cell Response the antibody response vaccination against COVID-19 Vaccinations were assessed X-linked agammaglobulinemia XLA [DOI] 10.1016/j.jaci.2022.04.002 PMC 바로가기 [Article Type] Controlled Clinical Trial
Complete blood cells count abnormalities in COVID-19 patients and their prognostic significance: Single center study in Makkah, Saudi Arabia전체 혈액 세포는 COVID-19 환자의 이상과 그 예후 중요성을 계산합니다: 사우디 아라비아 Makkah의 단일 센터 연구Article Published on 2022-06-012022-09-11 Journal: Saudi medical journal [Category] COVID19(2023년), SARS, 치료기술, [키워드] abnormality Admission age Anemia Blood blood cell blood count C-reactive protein clinical disease clinically Complete complete blood count coronavirus disease COVID-19 COVID-19 patient COVID-19 severity CRP Decision making decrease detectable disease effective intervention elevated evaluate feature female ferritin force group Inclusion Inflammation Inflammatory marker inflammatory markers leucocyte leucocytosis lymphopenia male management moderate N/L N/L ratio neutrophil neutrophil count neutrophilia non-survivor Non-survivors occurred Older age Organ failure outcome parameter Patient patients Peripheral blood Platelets platelets count prognostic prognostic significance. Rapid test regimen regimens Respiratory disease respiratory diseases Saudi Arabia security Serum ferritin Serum level Severe case severe COVID-19 disease severity Significant significant decrease significantly viral infection were excluded [DOI] 10.15537/smj.2022.43.6.20210893 PMC 바로가기 [Article Type] Article
Augmented neutralization of SARS-CoV-2 Omicron variant by boost vaccination and monoclonal antibodies추가 백신 접종 및 단일 클론 항체에 의한 SARS-CoV-2 Omicron 변이체의 증강 중화Article Published on 2022-06-012022-09-11 Journal: European Journal of Immunology [Category] COVID19(2023년), MERS, SARS, 변종, 진단, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 antibodies antibody Antibody binding appearance approved binding BNT162b2 boost boost immunization candidate caused clinically coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 Delta delta variant determine dominant Effective vaccines Efficacy Evidence flow cytometry immunization increase MONITOR monoclonal antibodies monoclonal antibody neutralization Neutralization assay neutralization assays neutralize neutralized Neutralizing neutralizing antibody omicron Omicron variant Omicron variants parental pathogenicity Protective pseudotyped SARS-CoV-2 recognize respiratory SARS-CoV-2 SARS-CoV-2 variants serum antibodies serum antibody serum titer serum titers severe acute respiratory syndrome Coronavirus Support therapeutic therapeutic antibodies titers Transmissibility vaccination Vaccine variant variants virus variant virus variants Wuhan strain [DOI] 10.1002/eji.202249841 PMC 바로가기 [Article Type] Article
Catwalk: identifying closely related sequences in large microbial sequence databasesArticle Published on 2022-06-012022-11-16 Journal: Microbial Genomics [Category] COVID19(2023년), SARS, 치료기술, [키워드] approach Bacterial Bacterial genomics bottleneck bypasse clinically coded comparison Comparisons cut-offs database develop faster Genome genomes identify implementation large sample microbial microbial relatedness Mycobacterium tuberculosis National Nim outbreak outbreak detection. SARS-CoV-2 SARS-CoV-2 genomes searched sequence Sequence analysis Sequencing similarity tested Transmission Tuberculosis viral sequences [DOI] 10.1099/mgen.0.000850 PMC 바로가기
Discovery of potential anti-SARS-CoV-2 drugs based on large-scale screening in vitro and effect evaluation in vivo대규모 in vitro 스크리닝 및 in vivo 효과 평가를 통한 잠재적 anti-SARS-CoV-2 약물 발굴Article Published on 2022-06-012022-09-11 Journal: Science China. Life sciences [Category] COVID19(2023년), SARS, 변종, 신약개발, 치료제, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus anti-SARS-CoV-2 Antiviral antiviral activity antiviral drug approved drug candidate caused Cell culture cisatracurium clinical clinically Compound coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 treatment cytotoxicity D614G D614G variant develop drug Drug repurposing drug resistance Drug screening drugs effective Efficacy Gilteritinib hamster hamster model. hamsters HeLa cell HeLa cells human ACE2 IL-6 in vitro in vivo induce life cycle mRNA pandemic passage Postinfection promoted Prophylactic protective effect provided pulmonary viral reduced Remdesivir Salinomycin SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 life cycle selected sertraline severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 shown suppressed the SARS-CoV-2 TNF-α transduced Treatment variety Vero E6 Vero E6 cell VERO E6 cells weight loss [DOI] 10.1007/s11427-021-2031-7 PMC 바로가기 [Article Type] Article
Evaluation of a Wastewater-Based Epidemiological Approach to Estimate the Prevalence of SARS-CoV-2 Infections and the Detection of Viral Variants in Disparate Oregon Communities at City and Neighborhood ScalesSARS-CoV-2 감염의 유병률을 추정하기 위한 폐수 기반 역학 접근 방식 평가 및 도시 및 인근 지역 규모의 이질적인 오레곤 커뮤니티에서 바이러스 변이체 감지Article Published on 2022-06-012022-09-11 Journal: Environmental health perspectives [Category] COVID19(2023년), SARS, 변종, 치료기술, [키워드] addition Affect Analysis Asymptomatic Asymptomatic cases authority B.1 city clinically communicable Community Concentration correlated correlation COVID-19 demography detection disease disparate door eight Epidemiology estimate Estimated event examined greater Health authority hotspot identify indicated Infection infections location log nasal swab neighborhood Pearson positive positive correlations Prevalence Previous studies previous study public health quantified Quantitative R 2 Randomized ranged reliability reported SARS-CoV-2 SARS-CoV-2 RNA SARS-CoV-2 variant SARS-CoV-2 variants scalability scale sequenced significantly Surveillance tested Treatment Variation variations wastewater [DOI] 10.1289/EHP10289 PMC 바로가기 [Article Type] Article
Combination anti-HIV antibodies provide sustained virological suppression Research Published on 2022-06-012022-10-05 Journal: Nature [Category] 바이오마커, 임상, 치료제, [키워드] Administered antibody Antiretroviral therapy antiviral agent baseline clinical trial clinically Combination combination therapy Complete develop double-blind effective enrolled Guidance half-lives HIV HIV infection Human immunodeficiency virus individual inhibit initiated neutralizing monoclonal antibodies neutralizing monoclonal antibody offer Open-label participant Placebo placebo-controlled trial plasma provided Randomized Serious Adverse Event single-arm trial study participant Study participants sustained therapy transfer Treatment Viraemia virological suppression virus with HIV [DOI] 10.1038/s41586-022-04797-9 [Article Type] Research